Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270591 · ClinicalTrials.gov registry record · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
A Phase 1 study of C-Met Exon 14 Mutation, sponsored by Haihe Biopharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 183
- Enrollment target
- 20
- Study locations
NCT04270591: Recruiting Phase 1 study of C-Met Exon 14 Mutation, sponsored by Haihe Biopharma Co..
NCT04270591 is a Phase 1 study of C-Met Exon 14 Mutation that is actively recruiting participants, run by Haihe Biopharma Co.. The registered enrollment target is 183 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (205% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04270591, a Phase 1 study of C-Met Exon 14 Mutation, is actively recruiting participants, sponsored by Haihe Biopharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 183 participants
- Enrollment target
- 20
- Study locations
Study Summary
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Primary Outcome
ORR as determined by an Independent Radiology Review Committee (IRRC) according to RECIST Version 1.1.
Conditions Studied
Interventions
- DRUG Glumetinib
Study Locations (20)
Beijing Municipality
- Beijing Cancer Hospital - Beijing
- Beijing Cancer Hospita - Beijing
- Peking Union Medical College Hospital - Beijing
Kentucky
- Norton Cancer Institute - Louisville
- The Oncology Institute of Hope & Innovation - Louisville
Anhui
- Anhui Province Hospital - Hefei
- The Chest Hospital of Anhui Province - Hefei
Hubei
- Hubei Cancer Hospital - Wuhan
- Wuhan Union Hospital - Wuhan
Jiangsu
- Jiangsu Cancer Hospital - Nanjing
- Jiangsu Province People's Hospital - Nanjing
Fujian
- Union Medical College Hospital Affiliated to Fujian Medical University - Fuzhou
Guangdong
- The First Affiliated Hospital of Guangzhou Medical University - Guangzhou
Guangxi
- Cancer Hospital Affiliated to Guangxi Medical University - Nanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 1 |
What NCT04270591 shows while recruiting
NCT04270591 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (205% higher).
The record links to 1 condition, with C-Met Exon 14 Mutation appearing as the primary indexed condition, and to 1 intervention - of which Glumetinib is the first listed.
NCT04270591 names 20 study sites across 14 states, led by Beijing Municipality, Kentucky, Anhui.
Frequently Asked Questions
What is clinical trial NCT04270591 about?
NCT04270591 is a clinical study titled "Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer". Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
What is the current status of trial NCT04270591?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 183 participants. The study started on 2019-07-15. Estimated completion is 2023-12-30.
What conditions does trial NCT04270591 study?
This clinical trial studies the following conditions: C-Met Exon 14 Mutation.
What interventions are being tested in trial NCT04270591?
The interventions under investigation include: Glumetinib (DRUG).
Who is sponsoring clinical trial NCT04270591?
This trial is sponsored by Haihe Biopharma Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04270591 being conducted?
This trial has 20 study locations across Kentucky, Anhui, Beijing Municipality, Fujian, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04270591's enrollment target sits among peer trials
183 298th of 2000 higher than 1,702 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
- NCT06922591 · 183 participants · Phase 1
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI